Mar 30, 2017 After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers Learn More
Mar 21, 2017 Cellectar Biosciences Further Deepens Intellectual Property Portfolio with Patent Grant for PET Imaging PDC Learn More
Mar 15, 2017 Cellectar Biosciences Reports 2016 Company Performance and Continued Progress in First Quarter 2017 Learn More
Mar 14, 2017 Newly Issued Japanese Patent For PDC Optical Agents Further Strengthens Cellectar Biosciences’ Intellectual Property Portfolio Learn More